US · BTMD
biote Corp.
- Sector
- Healthcare · Medical - Care Facilities
- Headquarters
- Irving, TX 75038
- Website
- biote.com
Price · as of 2024-12-31
$2.19
Market cap 101.44M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $28.36 | +1,194.98% |
| Intrinsic Value(DCF) | $1.76 | -19.63% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $1.31 | -40.05% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $53.40 | |||
| 2021 | $9.83 | $43.47 | $272.29 | $0.00 | $115.75 |
| 2022 | $4.55 | $287.26 | $0.00 | $0.00 | $0.00 |
| 2023 | $5.64 | $252.68 | $22.46 | $0.00 | $2.58 |
| 2024 | $4.26 | $28.36 | $2.85 | $0.00 | $1.31 |
AI valuation
Our deep-learning model estimates biote Corp.'s (BTMD) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $28.36
- Current price
- $2.19
- AI upside
- +1,194.98%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.76
-19.63% upside
Graham-Dodd
—
— upside
Graham Formula
$1.31
-40.05% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BTMD | biote Corp. | $2.19 | 101.44M | +1,195% | -20% | — | -40% | 3173.78 | -1.38 | 0.74 | 13.95 | — | -1.21 | 70.52% | 16.03% | 1.60% | -0.07% | -66.66% | 0.03% | -1.05 | 2.87 | 1.32 | 0.91 | 4.59 | -2915.00% | 638.00% | 6058.00% | 26.59% | 0.88 | -204.62% | 3.25% | 10313.00% | 7.08% | 6.88 | 5.60 | 1.10 | 1.87 |
| ABOS | Acumen Pharmaceuticals, I… | $3.14 | 190.2M | — | — | — | — | -0.73 | 0.41 | — | 0.68 | -1.26 | 0.41 | 0.00% | — | — | -45.60% | -248.14% | -37.27% | 0.16 | -28.03 | 6.46 | 6.21 | 0.06 | 5833.00% | — | 10014.00% | -114.95% | -3.12 | -187.66% | 0.00% | 0.00% | 0.05% | 0.59 | 0.78 | — | -1.94 |
| ACTU | Actuate Therapeutics Inc | $3.74 | 86.93M | — | — | — | — | -4.97 | 1301.78 | — | -5.05 | -5.09 | 1301.78 | 0.00% | — | — | 54.83% | 45.28% | -443.16% | 0.00 | 1344.27 | 1.05 | 0.98 | 0.34 | 9758.00% | — | 101.00% | -16.10% | -2.48 | 39.31% | 0.00% | 0.00% | 4.19% | -5.05 | -5.81 | — | -19.92 |
| ANIK | Anika Therapeutics, Inc. | $14.36 | 207.09M | +157% | -53% | -61% | — | -18.87 | 1.43 | 1.82 | -93.81 | — | 1.54 | 56.56% | -9.80% | -9.64% | -7.32% | -9.43% | -5.54% | 0.17 | -6.34 | 4.72 | 3.71 | 18.15 | -8016.00% | -591.00% | -28713.00% | 2.12% | 0.51 | 3.72% | 0.00% | 0.00% | 6.37% | -15.57 | 39.44 | 1.53 | 3.99 |
| INO | Inovio Pharmaceuticals, I… | $1.81 | 97M | +981% | -57% | — | +13,527% | -0.49 | 0.77 | 243.22 | 0.28 | — | 0.77 | 100.00% | -51616.91% | -49254.27% | -115.42% | 1958.18% | -75.49% | 0.17 | -632.05 | 2.77 | 2.70 | 0.52 | -3514.00% | -7383.00% | -1614.00% | -197.43% | -2.95 | 1821.69% | 0.00% | 0.00% | 131.88% | 0.26 | 0.28 | -134.48 | -23.30 |
| JYNT | The Joint Corp. | $8.80 | 133.66M | +524% | -50% | — | — | -19.20 | 7.93 | 3.14 | 48.14 | — | 7.93 | 77.92% | -3.62% | -11.11% | -37.58% | -64.57% | -10.01% | 0.04 | — | 1.52 | 0.56 | -8.37 | -1515.00% | 1104.00% | -1497.00% | 5.02% | 0.19 | 281.30% | 0.00% | 0.00% | 5.48% | -73.88 | 16.96 | 2.68 | 2.03 |
| LUCD | Lucid Diagnostics Inc. | $1.44 | 146.54M | +85,309% | -60% | — | — | -1.54 | 13.02 | 16.16 | -1.56 | — | 15.08 | -90.20% | -1059.64% | -1047.61% | -2956.43% | 5531.77% | -157.04% | 3.94 | -1771.23 | 1.07 | 0.97 | 0.02 | -1667.00% | 7900.00% | 3556.00% | -63.78% | -1.88 | 5379.70% | 0.00% | 0.00% | 0.00% | -1.50 | -1.54 | 15.90 | -12.37 |
| MCRB | Seres Therapeutics, Inc. | $8.74 | 79.07M | — | — | — | — | 875.27 | 8.64 | — | -1.50 | 14208.58 | 8.64 | 0.00% | — | — | -0.88% | -241.20% | 0.05% | 6.65 | — | 0.94 | 0.86 | -0.51 | 616.00% | — | 1888.00% | -125.16% | -3.61 | -296.22% | 0.00% | 0.00% | 8.38% | -1.48 | -1.21 | — | -12.11 |
| SCLX | Scilex Holding Company | $8.21 | 70.13M | +4,776% | -41% | — | — | -1.16 | -0.44 | 1.49 | -1.78 | — | -0.35 | 70.51% | -147.37% | -128.66% | 39.83% | 80.83% | -74.96% | -0.20 | -42.48 | 0.16 | 0.11 | -0.52 | -5668.00% | 2107.00% | -19198.00% | 22.92% | 0.07 | -18.75% | 0.00% | 0.00% | 106.43% | -1.43 | 6.16 | 2.10 | -13.47 |
| SPRO | Spero Therapeutics, Inc. | $2.17 | 122.26M | +1,351% | -86% | — | +2,434% | -0.61 | 0.91 | 0.88 | 0.09 | — | 0.91 | -101.67% | -152.91% | -142.91% | -89.62% | -436.22% | -46.81% | 0.09 | — | 2.19 | 2.15 | 0.67 | -39535.00% | -5377.00% | -2895.00% | -55.69% | -0.48 | -139.40% | 0.00% | 0.00% | 0.00% | 0.09 | 0.28 | -0.14 | -6.55 |
| VOR | Vor Biopharma Inc. | $15.44 | 105.82M | — | — | — | — | -0.59 | 0.71 | — | -0.07 | — | 0.71 | 0.00% | — | — | -94.52% | -282.56% | -66.29% | 0.33 | — | 5.19 | 4.94 | 0.43 | -286.00% | — | -145.00% | -145.39% | -5.35 | -232.90% | 0.00% | 0.00% | 79.21% | -0.07 | -0.09 | — | -5.73 |
About biote Corp.
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
- CEO
- Bret Christensen
- Employees
- 217
- Beta
- 1.15
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.76 ÷ $2.19) − 1 = -19.63% (DCF, example).